摘要
目的观察放化疗联合Ommaya囊置入治疗囊性脑转移瘤的有效性及安全性。方法 40例囊性脑转移瘤患者随机分为2组:Ommaya组24例,对照组16例。Ommaya组行Ommaya囊置入术,同时进行同步放化疗及瘤内化疗;对照组仅进行同步放化疗,均4周为1个疗程。2组均随访至2013年6月,比较2组的近期疗效、中位生存时间(MOS)、生存率及治疗相关不良反应。结果 Oommaya组治疗后客观有效率为91.7%,高于对照组62.5%(P<0.05)。Oommaya组的中位生存期为16月,对照组的中位生存期为6月。Ommaya组6个月、1年、2年生存率分别为83.3%、75.0%和25.0%,明显高于对照组的50.0%、18.8%和0(P<0.05)。患者的耐受性好,2组相关不良反应比较差异无统计学意义(P<0.05)。结论放化疗联合Ommaya囊内化疗治疗囊性脑转移瘤,其疗效优于单纯放化疗,且不良反应轻,患者耐受性好。
Objective To observe the efficacy and safety of chemoradiotherapy combined Ommaya sac placement for treatment of cystic brain metastases.Methods 40 cases of cystic brain metastases were randomly divided into two groups：Ommaya group of 24 patients,control group of 16 patients,Ommaya group underwent Ommaya capsule implantation,concurrent chemoradiotherapy and intratumoral chemotherapy;control group for concurrent chemoradiotherapy are four weeks of a course of treatment.Two groups were followed up to June 2013,compared two groups of short-term effect,the median survival time（MOS）,survival,and treatment-related adverse reactions.Results The Ommaya group after treatment,objective response rate was 91.7%,higher than 62.5%of the control group（P0.05）.Ommaya group,the median survival time was16 months,in the control group,the median survival time was 6 months.Ommaya group at 6 months,1-year,2-year survival rates were 83.3%n,75.0%and 25.0%,significantly higher than 50.0%,18.8%,and 0（P0.05）.Well tolerated by patients,Iwo groups of related adverse reactions was no significant difference（P0.05）.Conclusion Chemoradiotherapy combined Ommaya sac placement for treatment of cystic brain metastases,its efficacy is superior to chemotherapy alone,and the adverse reactions were mildly,patients tolerated well.
出处
《疑难病杂志》
CAS
2014年第1期30-33,共4页
Chinese Journal of Difficult and Complicated Cases
